BackAcasti Pharma Overview

Acasti Pharma Current Cash

Track Acasti Pharma's current cash ($17M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$16.98M
↓ 23.30% YoYΔ $-5.16M vs prior year quarter

Peer average

Loading

Acasti Pharma Current Cash History

Loading

Acasti Pharma vs. peers: Current Cash Comparison

Loading

Acasti Pharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Acasti Pharma (ACST) FAQ

Acasti Pharma (ACST) currently reports a current cash of $17M as of March 2026. That compares with $22M in the prior-year period — down 23.3% year over year. Use the charts on this page to explore Acasti Pharma's current cash history and peer comparisons.

Acasti Pharma's current cash decreased from $22M to $17M — a 23.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acasti Pharma reported $17M in current cash as of March 2026. That compares with $22M in the prior-year period — down 23.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acasti Pharma, and consider following ACST for alerts when major investors trade the stock.

Acasti Pharma is classified in the Healthcare sector. On current cash, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACST with unrelated industries.